Innovent Biologics will showcase seven oral presentations at ASCO 2025, featuring breakthrough clinical data for its novel PD-1/IL-2α-bias bispecific antibody IBI363 in melanoma, colorectal cancer, and non-small cell lung cancer.
Innovent Biologics presented Phase 1 data for IBI343, an anti-CLDN18.2 ADC, at the ESMO Asia Congress 2024, showing efficacy in advanced pancreatic cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.